Two weeks ago, Cellectis (ALCLS) and Pfizer (PFE) struck an agreement to develop new chimeric antigen receptor (CAR)-T-based therapies for oncology. Pfizer will pay $80M upfront and up to $185M in milestones per product plus royalties on sales. Additionally, Pfizer has acquired a 10% stake in Cellectis. Pfizer has exclusive rights to develop 15 […]
July 1 Biotech Update
It was a good morning in the sector with some positive news and momentum, although we seemed to have faded a little. As I have been saying for awhile, I think the sector has a good shot to hit new all-time highs as long as the macro environment does not turn bearish. I do not […]
June 30 Biotech Update- Back in the Saddle Again
Vacation is over and I am back to the grind (although I cannot really call what I do a grind as it is enjoyable). This is extra early today as I have a lot of catching up to do today and wanted to get some thoughts out there before I get caught up in other […]
RTRX – In a Consolidation Mode
Retrophin, Inc. (RTRX) –Nasdaq During the last 13 trading days, RTRX trading along the 200-Day moving avarage (red line) with small candlestick (doji) on a descending volume confirming the consolidation mode. The MACD moving to the positive territory along with the RSI positive momentum as well. the next resistance line is the 50-Day moving average […]
Catalyst Watch – Vol. 2, Edition 21 (6/26/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates MNKD: PDUFA […]
Catalyst Watch – Vol. 2, Edition 20 (6/20/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates No updates […]
June 20 Biotech Update
I am glad that I did not miss too much yesterday but it is usually the case that a day or week off does not dramatically change your perspective. It was another good morning for biotechs and I still believe that we are going to make a run at the all-time sector highs if the […]
June 18 Biotech Update
The sector (and market really) has been choppy since late yesterday morning. I would not read anything into these movements as it is a combination of low volume summer doldrums and the lack of any strong short term trend. As I have been saying for awhile, there will be a positive bias to trading for […]
June 17 Biotech Update
The sector continues to do well and if the broader market correction holds off we may be making a move to all-time highs but I would remain cautious. In any case, the sector seems healthy at this point despite heading into the summer doldrums and a seasonally weak period. 1. So the one name I […]
ASCO small caps: SNSS KPTI CYTR IMUC ZEL
Sunesis (SNSS) The company presented a poster of an MD Anderson-sponsored trial of its investigational drug voseroxin plus decitabine. There was intriguing data with regard to the response rates. 30 patients (pts) were evaluable for response; 13 (43%) achieved CR, 6 (20%) CRp, and 3 (10%) CRi, for an ORR of 81% with no evidence […]
June 16 Biotech Update- Good Data at EHA
A generally good start to the week for the sector with perhaps the good data out of EHA providing a nice early bump to sentiment. It seems to me that EHA was much more significant for small caps and biotech this year than ASCO despite getting a lot less play heading into the weekend. So […]
Catalyst Watch – Vol. 2, Edition 19 (6/13/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates CNAT: Holding […]
June 13 Biotech Update
This is going to be a quick update as there is not a lot of new in the market and I have a busy morning and afternoon. That being said there are two pieces of news that I thought was interesting and worth writing about. 1. CELG opted in and grabbed the global license for […]
June 5 Biotech Update
The market looks like it is teetering on the edge and perhaps it is the ISIS march across northern Iraq that will be the impetus to send it into the correction. What is interesting is that the biotech sector has held up well in this market weakness (although the weakness has been relatively minor at […]
June 11 Biotech Update
Another relatively slow summer day in the market in terms of trading but the sector seemed to outperform the broader market. Even with that marginal outperformance, I would not read anything new into in that I still believe that the macro is going to drive the next move. That being said I would not be […]
June 10 Biotech Update
Yesterday was a busy day and ended up being a little crazier than I planned but I am not back in the office and ready to think about some biotech. I did not have a chance to check the market yesterday so I am not sure how it traded but it seems like it is […]
June 6 Biotech Update
Today was the first day in a little while that the sector seemed noticeably weaker than the broader market. Perhaps this is simply natural variability, perhaps it is simply a slow trading day with random price action, or perhaps it is an early warning signal for a broader market correction. What seemed interesting is that […]
June 5 Biotech Update
Basically a mixed day in the sector, which is perhaps to be expected with so many traders focused on the ECB decision. Oddly it seemed that most thought there would be a significant move but the market basically yawned away the decision. The day, of course, is still young so perhaps there are more fireworks […]
Catalyst Watch – Vol. 2, Edition 18 (6/3/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: Updates ETRM: As […]
June 4 Biotech Update- The Post-ASCO Blue
So another ASCO is in the books and it seems like a fairly bland conference with relatively few significant stock reactions. Over the next couple of days I will sort out both what I saw as the major themes in the data but also the elusive “buzz.” In other words, there are the facts as […]
